Insight Molecular Diagnostics Inc. (IMDX) Stock Forecast
IMDX analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 5 analysts
- Price target
- $8.25 average of analyst targets
- Upside to target
- +174.1% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.22
- 52-week range
- $2.55 – $8.48
IMDX analyst ratings
5 analystsNumber of analysts at each rating.
IMDX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
IMDX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.22 | −$0.24 | −$0.20 | −$0.23 | +5.7% | 2 |
| Current fiscal year (2026) | −$0.93 | −$0.93 | −$0.92 | −$1.65 | +50.3% | 2 |
| Next fiscal year (2027) | −$0.80 | −$0.84 | −$0.76 | −$0.93 | +13.5% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
IMDX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $244,280 | $100,000 | $300,000 | −6.0% | 5 |
| Current fiscal year (2026) | $966,200 | $400,000 | $1.7M | −76.2% | 5 |
| Next fiscal year (2027) | $6.7M | $1.0M | $11.9M | +589.5% | 5 |
IMDX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
IMDX revenue: reported and forecast
IMDX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.18 | −$0.20 | −$0.22 | −$0.22 | −$0.22 | +22.2% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.85 | −$0.93 | −$0.93 | −$0.93 | −$0.93 | +8.8% | 0 up · 1 down |
| Next fiscal year (2027) | −$0.78 | −$0.84 | −$0.80 | −$0.80 | −$0.80 | +2.6% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
IMDX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; IMDX beat in 5 of 12.
What analysts expect from IMDX
5 analysts cover Insight Molecular Diagnostics; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $8.25, 174.1% above the latest close of $3.01. Analysts expect earnings of −$0.93 per share for 2026, +50.3% from a year earlier. For 2027 the average estimate is −$0.80 per share on revenue of $6.7 million. Insight Molecular Diagnostics beat the EPS estimate in 5 of the last 12 quarters.
Related: IMDX income statement, IMDX key metrics, IMDX chart. See the IMDX stock overview for the latest quote and news.
IMDX forecast FAQ
What is Insight Molecular Diagnostics's price target?
The average analyst price target for Insight Molecular Diagnostics is $8.25, 174.1% above the latest close of $3.01.
Is Insight Molecular Diagnostics a buy, hold or sell?
Of 5 analysts covering Insight Molecular Diagnostics, 2 rate it a strong buy, 1 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Insight Molecular Diagnostics's EPS forecast?
Analysts forecast −$0.93 per share for 2026 (range −$0.93 to −$0.92); for 2027 the estimate is −$0.80.
What is Insight Molecular Diagnostics's revenue forecast?
The average revenue estimate for 2026 is $1.0 million, growth of −76.2%; for 2027 it is $6.7 million.
When does Insight Molecular Diagnostics report earnings?
Insight Molecular Diagnostics is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes; the EPS estimate is $-0.22.
Does Insight Molecular Diagnostics usually beat earnings estimates?
Insight Molecular Diagnostics reported EPS at or above the analyst estimate in 5 of the last 12 quarters.